The Full Male Hormone Cascade: What to Measure and Why

Thomas was fifty-one when he started piecing together what he assumed was a midlife crisis and what turned out to be a medical problem. The gym sessions that used to produce results stopped producing anything — three months of consistent training, zero body composition change. His motivation had flattened into something he privately called a fog. The sexual interest that had defined the first twenty-five years of his marriage had dropped to a frequency that bothered him and confused his wife in roughly equal measure. He was sleeping eight hours and waking up exhausted anyway. His attention at work — previously his edge — had gone scattered and effortful in a way it had never been before.

His annual physical included a testosterone test, at his own request. His doctor called with the results: total testosterone 412 ng/dL. Normal. Reference range 300-1000 ng/dL. At 412, he was inside the range. His doctor suggested more exercise and better sleep. Thomas already exercised five times a week and slept eight hours a night. The suggestion felt like being told to try harder at something he was already maxed out on.

A urologist specializing in men’s health eventually ran the complete panel. Total testosterone confirmed at 412 ng/dL. But SHBG was 78 nmol/L — high — putting his calculated free testosterone at 6.2 ng/dL, bottom quartile for his age. LH was 1.8 mIU/mL — low, pointing toward pituitary inadequacy rather than testicular failure driving the problem. Estradiol was 48 pg/mL — elevated, with adipose-derived aromatase converting his testosterone to estrogen and further suppressing his LH signal on top of everything else. DHEA-S sat at the 15th percentile for his age. And prolactin was 22 ng/mL — elevated, warranting an MRI to rule out a pituitary adenoma. (The MRI came back negative. Idiopathic hyperprolactinemia from chronic stress, directly suppressing his LH signal.)

Total testosterone: normal. Everything else: a coherent picture of secondary functional hypogonadism, with multiple addressable causes stacked on top of each other. The complete panel changed everything — not just the diagnosis, the entire treatment direction. This article is the guide to that panel.

The Male Hormonal System: A Network, Not a Single Number

Male hormonal health is a system — multiple interacting components, regulatory feedback loops, precursor-product relationships, downstream conversion pathways all running at once. Evaluating it through a single total testosterone measurement is like evaluating a company’s financial health through one revenue number. You get a data point. You miss the margin, the debt, the cash flow, the competitive position — the stuff that actually determines whether the company’s thriving or quietly failing.

The hypothalamic-pituitary-gonadal (HPG) axis is the regulatory system here. The hypothalamus produces GnRH (gonadotropin-releasing hormone) in pulses every 60-90 minutes, stimulating the anterior pituitary to release LH (luteinizing hormone) and FSH (follicle-stimulating hormone). LH stimulates Leydig cells in the testes to produce testosterone. FSH stimulates Sertoli cells to support spermatogenesis. Testosterone feeds back negatively on both the hypothalamus and pituitary, keeping the whole loop in check. Disrupt this axis at any level and you get a different clinical pattern, requiring a different intervention.

Knowing where in this axis the disruption sits is the difference between targeted treatment and guessing. The complete male hormone panel pinpoints the disruption precisely — which is why ordering only total testosterone is a bit like a mechanic listening for a knock without popping the hood.

The Complete Panel: What to Measure and What Each Marker Tells You

Total Testosterone: The total amount in circulation, produced primarily (95%) in testicular Leydig cells with a small adrenal contribution. Follows a diurnal rhythm — peaks 7-10 AM, declines 20-30% through the afternoon. Testing has to happen as a morning fasting draw between 7 and 10 AM for a clinically valid result. An afternoon draw in a man with clinical hypogonadism symptoms can get interpreted as “normal” when a morning draw would show significant deficiency.

The “normal” range of 300-1000 ng/dL spans a 3.3-fold range within “normal” — a man at 310 ng/dL and a man at 970 ng/dL are both technically normal but live in physiologically different hormonal realities. The functional optimal range — the zone tied to best body composition, libido, energy, mood, and cognitive function in outcome studies — generally runs 550-900 ng/dL for most men, though individual optimal levels vary. Some men feel great at 500. Others need 800+ for the same result. The symptom picture leads; the number just confirms the direction.

Free Testosterone:

Only 2-3% of testosterone circulates unbound (free), and that’s the biologically active fraction — available to enter cells and bind androgen receptors (AR), activating androgen-responsive gene programs in muscle, bone, brain, sexual organs, and skin. Most testosterone (roughly 45-55%) is bound tightly to SHBG (biologically inactive), and another 40-50% is loosely bound to albumin (potentially bioavailable, usually measured separately as calculated bioavailable testosterone). Free testosterone is most accurately calculated from total testosterone and SHBG via the Vermeulen formula — more reliable than a direct immunoassay for most clinical purposes. Optimal free testosterone: generally above 15 ng/dL (roughly 75-100 pg/mL by some lab unit conventions), though lab units and calculation methods vary enough that comparing against the same lab’s own reference range matters.

SHBG (Sex Hormone-Binding Globulin):

A glycoprotein the liver produces that binds testosterone (and estrogens) with high affinity, making them biologically unavailable. It’s the single most important determinant of free testosterone — men with high SHBG have significantly lower free testosterone relative to total than men with low SHBG. SHBG rises with: dietary patterns producing low insulin (very low-carbohydrate diets paradoxically raise SHBG and lower free testosterone despite not touching total testosterone), aging (roughly 1-2% per year from middle age on), hyperthyroidism, excess estrogen (including obesity-related aromatization), liver disease, certain anticonvulsant medications, and growth hormone deficiency. SHBG falls with: insulin resistance and hyperinsulinemia (the mechanism by which obesity lowers SHBG and raises free testosterone in some obese men, partially offsetting the aromatase-driven drop in total testosterone), hypothyroidism, anabolic steroid use, and growth hormone therapy.

LH (Luteinizing Hormone):

The pituitary’s signal to Leydig cells, and the single marker giving the most important diagnostic distinction in male hypogonadism: primary versus secondary. Primary hypogonadism — testicular failure — LH is high or high-normal (the pituitary shouting at testes that can’t respond), testosterone is low. Secondary hypogonadism — pituitary or hypothalamic failure — LH is low or inappropriately normal (the brain never sends the signal), testosterone is low. These two patterns need completely different treatment: primary hypogonadism usually needs direct testosterone replacement, since the testes can’t be stimulated into producing more; secondary hypogonadism may respond to medications that boost the LH signal instead — clomiphene, enclomiphene, HCG.

Skip LH, and treatment decisions get made blind to the actual mechanism.

FSH (Follicle-Stimulating Hormone):

Drives spermatogenesis in Sertoli cells. Critically important for men who want to preserve or restore fertility. Testosterone replacement therapy (TRT) suppresses LH and FSH — eliminating the intratesticular testosterone spermatogenesis needs, typically causing a significant drop in sperm count (oligospermia or azoospermia) and testicular atrophy within 6-12 weeks of starting. Any man who hasn’t definitively ruled out future fertility should get a baseline FSH before any TRT decision and should seriously weigh fertility-preserving alternatives — HCG to maintain intratesticular testosterone, enclomiphene to stimulate the HPG axis — before starting testosterone replacement outright.

Estradiol (E2) — measured by sensitive assay:

Men produce estradiol through aromatase enzyme conversion of testosterone, mostly in adipose tissue, liver, and brain. It isn’t just a female hormone in men — it’s essential for male bone density, cardiovascular health, libido, cognitive function, and mood. The question isn’t whether estradiol is present but whether it sits in the right range relative to testosterone. Elevated estradiol in men (above 40-50 pg/mL by most functional standards) suppresses the HPG axis through negative feedback (cutting LH and testosterone further), can cause gynecomastia (breast tissue development in roughly 1-3% of men with elevated estradiol), and impairs libido and mood. One technical note that matters a great deal: estradiol has to be measured by a sensitive LC-MS/MS assay specifically validated for male concentrations. Standard immunoassay estradiol tests, built for the wider female range, are inaccurate at male concentrations and produce unreliable results. Specify “estradiol, sensitive” or “estradiol, LC-MS/MS” when ordering. Don’t skip this.

DHEA-S (Dehydroepiandrosterone Sulfate):

The most abundant steroid hormone in human circulation, produced mainly by the adrenal zona reticularis. It’s an androgen precursor — converts to testosterone and estrogens in peripheral tissues. Peaks in the mid-to-late 20s and declines roughly 1-2% per year after that — the most consistent aging biomarker in human endocrinology. Low DHEA-S associates with fatigue, low libido, reduced stress resilience, impaired immune function, and accelerated cardiovascular aging across multiple observational studies. Unlike testicular testosterone, which represents one hormonal system, DHEA-S represents adrenal androgenic reserve — a distinct system that can run low even when testicular testosterone looks normal, and one directly implicated in the fatigue and mood symptoms many men with “normal testosterone” chalk up to aging.

Prolactin: Best known as the lactation hormone, but its direct effect on male hormonal function is underappreciated. Elevated prolactin suppresses GnRH pulsatility in the hypothalamus, reducing LH and FSH release and consequently reducing testosterone production. That’s the mechanism by which medications that raise prolactin — antipsychotics, some antidepressants, metoclopramide, certain anti-nausea drugs — produce hypogonadism as a side effect. Even modest prolactin elevation (20-40 ng/mL, against a normal male range of 2-18 ng/mL) can significantly suppress testosterone, tank libido, and cause erectile dysfunction. Prolactin above 100 ng/mL warrants a pituitary MRI to rule out prolactinoma — a benign pituitary adenoma, the most common functioning pituitary tumor, and highly treatable with a dopamine agonist medication (cabergoline).

Secondary Hypogonadism: The Most Treatable Pattern

Thomas’s case — low free testosterone from elevated SHBG, low LH from elevated prolactin, high estradiol completing the suppressive feedback loop — is secondary hypogonadism (sometimes called hypogonadotropic hypogonadism), with several reversible contributors stacked on top of each other. This is the most clinically important pattern to identify, because it’s often fully reversible without ever touching direct testosterone replacement.

The reversible contributors to secondary hypogonadism are far more common than most clinicians appreciate:

Sleep apnea:

CPAP treatment for obstructive sleep apnea consistently raises testosterone — in some studies by 15-30% — because nocturnal hypoxia from apneic episodes directly suppresses LH and testosterone production during the testosterone peak that happens during sleep. Men with testosterone in the 300-450 ng/dL range and untreated sleep apnea should get screened for apnea before any testosterone replacement decision.

Obesity: Adipose tissue carries high aromatase activity, converting testosterone into estradiol. The elevated estradiol from obesity suppresses the HPG axis through negative feedback, cutting LH and testosterone further. Elevated insulin from obesity lowers SHBG, partly raising free testosterone — but the net effect in most obese men is suppressed total testosterone, elevated estradiol, and an impaired HPG axis. Weight loss reverses this: a 10-15% weight loss in overweight men consistently and substantially raises testosterone — sometimes by 200-300 ng/dL — through reduced aromatase activity and a restored HPG axis.

Opioid medications:

Among the most underappreciated causes of acquired hypogonadism there is. Opioid-induced androgen deficiency (OPIAD) affects an estimated 70-90% of men on chronic opioid therapy for pain — opioids potently suppress GnRH secretion through μ-receptor activity in the hypothalamus, producing secondary hypogonadism within weeks of starting chronic therapy. Rarely disclosed to patients. Rarely tested by the physicians prescribing it. A significant cause of fatigue, depression, sexual dysfunction, and osteoporosis in men on long-term opioids. Any man on chronic opioids with hypogonadal symptoms should get testosterone testing with a full panel interpretation, not a shrug.

Hyperprolactinemia: Whether idiopathic (as in Thomas’s case), stress-induced, medication-induced, or from a prolactinoma, elevated prolactin is one of the most directly addressable causes of secondary hypogonadism around. Cabergoline (a dopamine agonist) normalizes prolactin with a high success rate in both idiopathic hyperprolactinemia and prolactinoma, and testosterone typically recovers within 6-12 weeks of prolactin normalization — with zero testosterone medication involved.

Chronic psychological stress and cortisol elevation: Sustained cortisol elevation suppresses GnRH pulsatility, reduces LH, and directly impairs Leydig cell testosterone production. “Stress lowers testosterone” isn’t a figure of speech — it’s a direct neuroendocrine mechanism. Men who address the underlying stressor, put in evidence-based stress reduction (particularly better sleep and dialing back training volume if overtrained), and see cortisol normalize frequently see testosterone recover in step.

Testosterone Optimization vs. Testosterone Replacement: Different Goals, Different Tools

A framework error drives a lot of poor clinical decisions here: conflating testosterone optimization (helping the body produce more of its own testosterone) with testosterone replacement therapy (exogenous testosterone, which suppresses the body’s own production entirely). Different risk profiles. Different effects on fertility. Different appropriate indications.

• Non-pharmacological optimization (always first): Resistance training — particularly compound barbell movements (squat, deadlift, bench press, overhead press) at moderate-to-high intensity — acutely elevates testosterone by 15-25% post-exercise and chronically raises baseline testosterone through adaptations in Leydig cell function and HPG axis sensitivity. Sleep optimization: below 5 hours a night reduces testosterone by 15-25% (Leproult and Van Cauter, JAMA 2011 — one of the most cited single sleep deprivation studies out there). Every hour of sleep below optimal costs measurable testosterone. Alcohol reduction: alcohol acutely suppresses testosterone through impaired Leydig cell function, elevated aromatase activity, and hypothalamic suppression. Chronic daily alcohol use is one of the most reliably documented causes of reduced testosterone period. Zinc repletion in deficient men: zinc is both a cofactor for testosterone synthesis and an aromatase inhibitor — deficiency reduces testosterone, and supplementing deficient men — bisglycinate absorbs best — consistently raises it. Vitamin D optimization to 50-70 ng/mL: correlates with higher testosterone across multiple large observational studies — the mechanism runs through VDR-mediated gene expression in Leydig cells.
• SERM-based optimization (clomiphene, enclomiphene): Selective estrogen receptor modulators block estrogen feedback on the hypothalamus, releasing the negative feedback brake on GnRH pulsatility and thereby raising LH and endogenous testosterone production. Clomiphene citrate (Clomid) has been used off-label for this for decades. Enclomiphene — the trans isomer, minus the zuclomiphene (cis isomer) that produces estrogenic effects and side effects — is now FDA-approved (Androxal) for secondary hypogonadism. The key advantage of SERM therapy: it restores testosterone through the HPG axis itself, maintaining testicular function, volume, and fertility — sperm production is maintained or even improved, not suppressed. For men who want to keep fertility while raising testosterone, enclomiphene or clomiphene is the pharmacological choice before TRT enters the conversation.
• HCG (Human Chorionic Gonadotropin): An LH mimetic that directly stimulates Leydig cells to produce testosterone, bypassing the HPG axis entirely. HCG maintains testicular volume and sperm production, used either as standalone treatment for secondary hypogonadism or as an adjunct to TRT — to prevent the testicular atrophy and fertility loss TRT causes on its own. HCG alone can substantially raise testosterone in men with functional testes and secondary hypogonadism, sidestepping TRT entirely in the right candidates.
• Testosterone Replacement Therapy (TRT): Direct administration of exogenous testosterone via injection (testosterone cypionate or enanthate most commonly, weekly or fortnightly on a schedule the prescriber sets against bloodwork), transdermal gel (Testim, Axiron, AndroGel), subcutaneous pellet (inserted in gluteal tissue every 3-4 months), transdermal patch, or oral testosterone undecanoate (Jatenzo, an oral TRT that avoids first-pass liver metabolism). Highly effective — normalizes testosterone reliably, resolves hypogonadal symptoms, improves body composition, bone density, and sexual function in hypogonadal men. The risks requiring informed consent and monitoring: suppression of LH/FSH causing testicular atrophy and infertility (most men on TRT who still want fertility need HCG alongside it, or should switch to SERM therapy instead); polycythemia (elevated hematocrit — testosterone stimulates erythropoiesis; hematocrit needs monitoring, with phlebotomy initiated above 54%); possible PSA acceleration (needs baseline and ongoing monitoring); and potential cardiovascular effects (current evidence is reassuring — the TRAVERSE trial found no increased MACE with TRT versus placebo in hypogonadal men).

DHT, 5-Alpha Reductase, and the Hair Loss Consideration

Dihydrotestosterone (DHT) is produced from testosterone by the 5-alpha reductase enzyme in peripheral tissues — skin, prostate, scalp, liver especially. DHT is 3-5 times more potent than testosterone at androgen receptors. It’s the primary androgen behind male sexual differentiation, prostate gland growth, and genetically-driven male pattern hair loss (androgenetic alopecia).

The DHT-prostate relationship matters clinically for men on TRT. Testosterone supplementation gives 5-alpha reductase more substrate to convert into DHT. The saturation model of prostate androgen signaling (proposed by Morgentaler) suggests prostate cells are essentially saturated with androgens at relatively low testosterone concentrations — meaning raising testosterone from low to normal doesn’t proportionally increase prostate stimulation — but DHT-related concerns still belong in informed consent for TRT. PSA monitoring is standard of care: baseline PSA before starting TRT, retesting at 3 and 12 months initially, then annually after that.

5-Alpha reductase inhibitors (finasteride, dutasteride) reduce DHT by 70-90% and get used for both BPH treatment and male pattern hair loss prevention. One clinically important and underappreciated issue: Post-Finasteride Syndrome (PFS) — persistent sexual dysfunction, mood disturbance, and cognitive symptoms that continue after stopping the medication, in an estimated 2-15% of users. PFS is recognized in the medical literature and by the FDA, which has added warnings to finasteride’s prescribing information. Men considering 5-alpha reductase inhibitors for hair loss deserve genuinely informed consent about this risk, not the minimization some prescribers still offer. For those primarily worried about hair loss while on TRT, topical finasteride or topical spironolactone (which reduce scalp DHT with minimal systemic absorption) offer an alternative to systemic 5-AR inhibition.

Cardiovascular Risk, Metabolic Health, and Testosterone

The cardiovascular safety debate around testosterone therapy ran hot from roughly 2010 to 2023, fueled by conflicting retrospective studies and observational data pointing in opposite directions. The TRAVERSE trial — a large, prospective, randomized, double-blind, placebo-controlled trial of 5,204 middle-aged and older hypogonadal men, published in the New England Journal of Medicine in 2023 — is the most definitive data available now. Findings: testosterone replacement did not increase the rate of major adverse cardiovascular events (MACE — heart attack, stroke, cardiovascular death) versus placebo over a mean follow-up of 33 months. There was, however, a statistically significant increase in atrial fibrillation (3.5% vs 2.4%) and pulmonary embolism (0.9% vs 0.5%) in the testosterone group — findings that warrant specific risk-benefit conversation in men with an AF history or elevated VTE risk.

The broader metabolic context matters too: low testosterone associates with multiple cardiovascular risk factors — insulin resistance, visceral adiposity, dyslipidemia, hypertension, endothelial dysfunction. The link between low testosterone and cardiovascular disease in observational studies may reflect shared causes (metabolic syndrome, sleep apnea, aging) rather than testosterone deficiency being independently causal. What’s clear regardless: normalizing testosterone in hypogonadal men improves metabolic markers — lean mass up, fat mass down, better insulin sensitivity, better lipid profiles, better inflammatory markers — all of which independently predict better cardiovascular outcomes on their own. Weigh all the metabolic effects together, and the cardiovascular picture likely favors optimization over low testosterone for most men.

Monitoring During Testosterone Therapy

Appropriate monitoring during TRT protects safety and optimizes outcomes. The minimum protocol:

1. At 3 months after starting therapy: Complete hormone panel (total T, free T, SHBG, estradiol — to confirm dose adequacy and assess conversion), CBC with differential (hematocrit — polycythemia risk), PSA (baseline shift assessment), and comprehensive metabolic panel (liver function)
2. At 6 months: Repeat hormone panel and CBC if hematocrit was elevated at 3 months
3. Annually once stable: Complete hormone panel, CBC, PSA, and metabolic panel
4. Continuously: Blood pressure monitoring (testosterone modestly raises blood pressure in some patients through fluid retention), symptom assessment

The hematocrit target on TRT: below 54% — the threshold above which phlebotomy gets recommended and TRT dose should come down. Polycythemia from TRT thickens blood and carries elevated VTE risk — the most reliably documented cardiovascular adverse effect of TRT beyond the AF signal from TRAVERSE. Some patients with recurrent polycythemia on TRT may need to switch from injections (which produce supraphysiological peaks that maximally stimulate erythropoiesis) to transdermal delivery (steadier levels, less erythropoietic stimulation).

Estradiol management during TRT: aromatase inhibitors — anastrozole, letrozole — sometimes get prescribed alongside it to prevent excessive estradiol elevation. But aromatase inhibition in men carries its own risks — estrogen is required for male bone density, cardiovascular function, libido, and cognitive function. Aggressive AI use that drops estradiol below 20 pg/mL impairs all of that, sometimes producing joint pain, low libido (paradoxically), mood disturbance, and reduced bone mineral density. Current functional medicine consensus: treat an AI as something titrated cautiously against a measured estradiol in the 20-40 pg/mL range — not as a default component of every TRT protocol.

SHBG: The Underappreciated Regulator

Sex hormone-binding globulin deserves its own section, because it’s the single most misunderstood variable in male hormone optimization. Most men who get a testosterone evaluation never have SHBG measured at all. Most clinicians who do measure it treat the result as background noise. Both errors lead to systematic mismanagement.

SHBG is a glycoprotein produced mainly in the liver. It binds testosterone (and estradiol and DHT) with high affinity, rendering the bound fraction biologically inactive — it can’t cross cell membranes or bind androgen receptors. Only the unbound fraction (free testosterone, roughly 2-3% of total) and the loosely albumin-bound fraction (another 30-40%) are bioavailable. A man with total testosterone of 650 ng/dL and SHBG of 70 nmol/L has a free testosterone near 6 ng/dL — well below optimal. A man with total testosterone of 500 ng/dL and SHBG of 20 nmol/L has a free testosterone near 13 ng/dL — excellent. Same total testosterone range. Profoundly different hormonal reality underneath it.

What drives SHBG higher: aging (roughly 1-2% per year after 40, partly explaining age-related free testosterone decline even when total testosterone holds steady); hyperthyroidism (thyroid hormone directly stimulates hepatic SHBG synthesis); elevated estradiol (though the relationship runs complex and bidirectional); certain anticonvulsant medications (phenytoin, carbamazepine) and some antifungals; excess alcohol (paradoxically, alcohol raises SHBG despite suppressing testosterone synthesis at the same time); low body weight or anorexia; and genetic variation in the SHBG gene producing constitutionally high SHBG regardless of everything else.

What drives SHBG lower: obesity and insulin resistance (hyperinsulinemia suppresses hepatic SHBG synthesis — one of the few mechanisms by which metabolic syndrome directly “helps” a hormone marker, producing lower SHBG and thus higher free testosterone in obese men even as total testosterone often falls); hypothyroidism; glucocorticoid excess; anabolic steroid use (exogenous androgens suppress SHBG dramatically, part of why supraphysiological steroid cycles produce extremely high free testosterone); and high protein intake (protein, like insulin, suppresses hepatic SHBG production).

In clinical practice, SHBG can be nudged — imperfectly, but meaningfully. Men with high SHBG can sometimes lower it by improving insulin sensitivity (weight loss, exercise, berberine or metformin in insulin-resistant men), optimizing thyroid function (treating even subclinical hypothyroidism quietly raising SHBG through compensatory mechanisms), and making sure protein intake is adequate. The supplement boron has modest evidence for reducing SHBG by roughly 25-28% in short-term trials, apparently by competing for SHBG binding sites — though clinical significance remains debated. For men with genuinely elevated SHBG and symptomatic low free testosterone, danazol (a weak androgen that markedly suppresses SHBG) was historically used, though it’s largely been replaced by other approaches given the side effects. The more modern functional approach: fix the root causes, measure the response over 3-6 months, and only reconsider exogenous hormone therapy if SHBG-driven free testosterone deficiency persists despite the root-cause work.

For men already on TRT where high SHBG is blunting the effect: switching from weekly injections to twice-weekly or every-3.5-day dosing produces more stable serum levels and may reduce the SHBG-stimulating effect of peaks; using testosterone cypionate instead of longer-ester preparations may shift SHBG dynamics; and some clinicians prescribe low-dose oral oxandrolone as an SHBG suppressor within TRT protocols — an off-label strategy carrying the risks that come with any anabolic steroid addition.

The practical message: any male hormone panel that skips SHBG is incomplete. Total testosterone without SHBG is like measuring total cholesterol without particle size — a number that looks informative and misses the mechanism entirely. Free testosterone, calculated from total testosterone and SHBG via the Vermeulen equation (or measured directly by equilibrium dialysis in ambiguous cases), is the endpoint that actually matters clinically. Order both. Always.

Full Male Hormone: Your Questions Answered

1. What time of day should testosterone be measured?
   Morning, between 7 and 10 AM, fasting. Testosterone follows a circadian rhythm — peaking early morning, declining 20-30% through the afternoon. An afternoon blood draw can produce a result 20-30% below the same man’s morning peak, falsely suggesting deficiency. Clinically, if a man gets a low result from a non-morning draw, the test should be repeated as a morning draw before any decision gets made off of it. Conversely, total testosterone on TRT should ideally be drawn at trough — day before injection for weekly dosing, or 12 hours after last application for daily gels — to assess baseline maintenance, not peak.
2. What is the ideal testosterone level?
   More individual than the guidelines suggest, and best determined by symptom response rather than a number in isolation. Population outcome data suggests 550-900 ng/dL as the range where body composition, cardiovascular markers, cognitive function, and sexual function are generally optimized. Some men feel excellent at 500 ng/dL. Others need 800+ for the same result. Free testosterone in the upper quartile for age is the more physiologically relevant marker. The right target is wherever symptoms resolve and subjective well-being is good — verified by labs to confirm the direction is right, not dictated by them.
3. Does testosterone cause prostate cancer?
   The old “testosterone feeds prostate cancer” model has been substantially revised. The saturation model — prostate androgen receptors saturated at relatively low testosterone concentrations, meaning raising testosterone from low to normal doesn’t proportionally increase prostate stimulation — now fits the clinical evidence better than the simple “more testosterone equals more cancer” hypothesis. The TRAVERSE trial found no increased prostate cancer incidence in men on TRT versus placebo. Current clinical practice treats active prostate cancer as a contraindication to TRT, but successfully treated low-risk prostate cancer is no longer considered an absolute contraindication — a significant shift from fifteen years ago, when any prostate cancer history meant a lifetime TRT ban.
4. How does alcohol affect testosterone?
   Significantly, through several mechanisms at once: acute alcohol consumption impairs Leydig cell testosterone synthesis by disrupting the mitochondrial function steroidogenesis depends on; alcohol elevates aromatase activity in adipose tissue, boosting testosterone-to-estradiol conversion; and chronic alcohol use progressively damages the hypothalamic GnRH pulsatility that drives the entire HPG axis. Chronic heavy drinking associates with hypogonadism, testicular atrophy, and gynecomastia — elevated estradiol from aromatase plus reduced testosterone creates a genuinely unfavorable androgen:estrogen ratio. Even moderate but consistent drinking (3-4 units daily) produces measurably lower testosterone in chronic patterns. For men optimizing testosterone through lifestyle, cutting alcohol is one of the single most impactful changes available.
5. Can testosterone replacement therapy be reversed?
   HPG axis suppression from TRT is generally reversible after stopping, though the recovery timeline varies. Most men recover endogenous testosterone production within 3-6 months of discontinuing, with HPG axis recovery tracked through rising LH levels. Recovery tends to be faster and more complete in younger men, men who used TRT for shorter periods, and men without pre-existing HPG axis dysfunction. Post-TRT recovery can be accelerated with SERM therapy (enclomiphene or clomiphene) to stimulate LH production and Leydig cell recovery. For men considering TRT but uncertain about permanence, discussing an initial trial with a structured cessation plan built in from the start is a reasonable approach.
6. Is testosterone testing covered by insurance?
   Basic total testosterone is typically covered when ordered with a clinical indication — symptomatic evaluation of possible hypogonadism. The complete panel described here — total testosterone, free testosterone, SHBG, LH, FSH, estradiol sensitive, DHEA-S, prolactin — may require prior authorization or documentation for some components. Direct-to-consumer lab services (LabCorp Patient, Quest Health, Marek Health) allow self-ordering of comprehensive male hormone panels at transparent out-of-pocket prices, typically $150-250 for the complete panel, no insurance authorization needed.

Thomas’s prolactin was treated with cabergoline — a highly effective dopamine agonist, roughly 80% response rate in hyperprolactinemia. Within three weeks his prolactin normalized to 9 ng/mL. His LH rose from 1.8 to 5.4 mIU/mL over eight weeks. Total testosterone climbed from 412 to 602 ng/dL. Free testosterone, calculated against the same elevated SHBG, rose proportionally from 6.2 to 9.8 ng/dL — still not optimal because of SHBG, but meaningfully better. Estradiol came down to 32 pg/mL as the testosterone-to-estradiol ratio shifted with improved testicular function. He lost 14 pounds over four months without changing his diet — his restored metabolic rate and improved body composition reflected the anabolic and lipolytic effects of normalized testosterone. The fog lifted. The gym started producing results again. His marriage improved considerably as his libido and energy came back.

None of this needed testosterone replacement. It needed understanding what was actually wrong — a picture that only became visible once the complete panel was ordered. Total testosterone, in isolation, said nothing was wrong. The complete cascade told the whole story. That story was treatable. The treatment was precise. The result was transformative. That’s what the complete male hormone panel is for.

The Practical Framework: Applying Full Male Hormone Cascade In Real Life

References

• NIDDK Endocrine Diseases

Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map